Adlai Nortye Ltd.

Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on researching and developing pharmaceutical products. Its pipeline includes several drug candidates targeting various cancers. AN0025 is a small molecule EP4 antagonist in phase Ib trials for rectal and esophageal cancers, and in phase II for moderate to high-risk rectal cancer. AN9025 is an oral pan-RAS(ON) inhibitor in phase 1a for RAS-mutant cancers like pancreatic, lung, and colorectal adenocarcinomas. AN4035 is a CEACAM5-targeting antibody drug conjugate, and AN8025 is a tri-specific antibody fusion protein in phase Ia for advanced tumors. AN4005 is a small-molecule PD-L1 inhibitor in phase 1b to activate cancer immunity. The company also provides technology transfer and consulting services.

Adlai Nortye Ltd. is listed on the NasdaqGM exchange under the ticker symbol ANL. The company's stock is traded in US dollars (USD), which is the currency of its primary listing market. As a US-based company, its financial reporting and share pricing are conducted in USD, making it accessible to investors on the Nasdaq Global Market.

Adlai Nortye Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on the research and development of pharmaceutical products, particularly for cancer treatment. The company's pipeline includes small molecule inhibitors, antibody drug conjugates, and fusion proteins, all aimed at addressing various oncological conditions. This places it among clinical-stage biotech firms that develop novel therapies for unmet medical needs.

Adlai Nortye Ltd. is headquartered in North Brunswick, New Jersey, United States. The company was founded in 2004, giving it over two decades of history in the biotechnology space. As a clinical-stage company, it has been dedicated to advancing its pipeline of cancer therapies from early research through clinical trials. Its location in New Jersey places it within a major hub for pharmaceutical and biotech innovation in the US.

Adlai Nortye Ltd. generates revenue primarily through its technology transfer and consulting services business, in addition to its core focus on developing pharmaceutical products. As a clinical-stage company, it does not yet have approved drugs on the market, so its revenue from product sales is currently minimal or nonexistent. The company's pipeline includes multiple drug candidates in various phases of clinical trials, such as AN0025, AN9025, AN4035, AN8025, and AN4005, which target different cancers. If these candidates receive regulatory approval, they could become significant revenue sources in the future. For now, the consulting and technology transfer activities provide some income while the company advances its research.